Backgrounds/Aims: In some patients with chronic hepatitis, liver stiffness (LS) findings do not reflect fibrosis stage. This study was performed to evaluate whether acute liver inflammation could influence LS findings. Methods: Patients with acute hepatitis A admitted to our hospital were included. Hepatitis was classified on admission using serum ALT and bilirubin levels as inflammation phase, jaundice phase, or recovery phase. Patients who admitted during the recovery phase (whose ALT and bilirubin levels fell continuously during hospitalization) and therefore, their peak-ALT and peak bilirubin levels could not be determined were exduded. Enrolled patients underwent FibroScan during hospitalization and after discharge. Results: Seventy-six patients with acute hepatitis A were enrolled (median age, 29 years; 46 men and 30 women). Among them, 33 (43.4%) and 43 (56.6%) patients were admitted during the inflammation phase and jaundice phase, respectively. For patients admitted during the inflammation phase, mean (±SD) time from symptom-onset day to maximum ALT level was 7 (±3) days. For all patients, mean time from symptomonset to maximum bilirubin level was 11 (±4) days. Mean LS during admission was 8.9 (±3.3) kPa (median, 8.4 kPa). LS was significantly correlated with serum bilirubin level, which was the only factor found to be significantly associated with the increased LS (>7.08 kPa). In all patients, LS increased gradually from the symptom-onset and peaked at 8-9 days later. Conclusions: Severe hepatic inflammation can affect the LS findings and thus, care is required when assessing fibrosis stage using LS measurement in patients with severe inflammation. (Korean J Hepatol 2008;14:465-473) 
Introduction
The accurate assessment of the liver fibrosis extent is essential for predicting prognosis and determining appropriate management in patients with chronic liver diseases. 1 Liver biopsy is still considered the gold standard, 2 but it is invasive and can lead to life-threatening complications. 3, 4 Furthermore, its accuracy for assessing fibrosis is suspected due to sampling errors [5] [6] [7] [8] [9] and intraand interobserver discrepancies. [9] [10] [11] In contrast, liver stiffness (LS) determined using Fibroscan is entirely non-invasive, and reduces the potential for sampling errors, 12 because the liver volume measured is 100 times greater than that of liver biopsy specimens. In addition, LS measurements are reproducible with low intraand interobserver variabilities. 13, 14 Furthermore, the correlation between LS and fibrosis stage seems to be unaffected by steatosis or degree of necroinflammation 13, 15, 16 and several studies have suggested that LS is highly accurate for assessing liver fibrosis. 12, [15] [16] [17] [18] [19] [20] [21] [22] Unfortunately, in some patients with chronic hepatitis, LS and liver biopsy findings disagree and it has been suggested that this is usually caused by biopsy limitations and the design of the METAVIR grading system, 13, 23 rather than influence of liver inflammation on LS findings.
However, the majority of patients enrolled in these studies had chronic hepatitis C with only marginal transaminases and bilirubin level deviations, and thus, the effects of such deviations on LS would have been difficult to determine. [12] [13] [14] [15] [16] Furthermore, it was recently suggested that LS is dependent on liver inflammation in chronic hepatitis B 14 and acute hepatitis. 24, 25 Although the relation between liver inflammation and LS has been documented, 24, 25 relations between LS and transaminases and bilirubin levels remain unclear, because in previous studies cohort sizes were small and a focus was placed only on the relation between LS and alanine aminotransferase (ALT) levels. Therefore, we undertook this study to evaluate the changes in LS during the course of acute hepatitis A (AHA) and to identify those factors that influence LS.
Patients and Methods

Patients
This study is a retrospective observational study. We performed chart review of all conse- At the time LS measurements were made, the following biochemical tests were also performed; serum aspartate aminotransferase (AST), ALT, alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), and bilirubin level.
Determination of acute hepatitis A phase
Serum ALT and bilirubin levels were checked every 1-3 days during hospitalization and the days when serum ALT and bilirubin peaked (peak-ALT and peak-bilirubin) were determined.
In addition, the day of onset of acute hepatitis symptoms (Sx-onset) was determined by history taking.
Phases of AHA at time of hospitalization were determined as follows: inflammation phasewhen a patient was hospitalized before peak-ALT, jaundice phase -when hospitalized after peak-ALT, but before peak-bilirubin. were considered reliable.
A recent study found that LS in healthy subjects is 5.49±1.59 kPa. 26 Therefore, the ULN of LS was set at 7.08 kPa (i.e. mean+one standard deviation), and thus higher LS values were considered elevated. and 0.007, respectively), mean times from Sxonset to peak-ALT or peak-bilirubin were not Sx-onset day, the day of acute hepatitis symptom onset; peak-ALT day, the day when serum ALT levels peaked; peak-bilirubin day, the day when serum bilirubin levels peaked. AST, aspartate aminotransferase; ALT, alanine aminotransferase; Sx-onset day, the day of acute hepatitis symptom onset; peak-ALT day, the day when serum ALT levels peaked; peak-bilirubin day, the day when serum bilirubin levels peaked; LSM-performed day, the day when liver stiffness was measured.
significantly different for patients hospitalized during the inflammation and jaundice phase (Table 1) . two groups (Table 3 ). In addition, multivariate binary regression analysis also identified serum bilirubin level as being a significant factor of increased LS (odds ratio, 1.763; 95% CI, 1.198-2.594; P=0.004; Table 4 ).
Liver stiffness according to the duration from symptom-onset day to LSM-performed day
A second LS measurement was performed after discharge in 57 patients (75%) at 47±16 days after Sx-onset and a third in 4 patients at 79±12 days after Sx-onset. The LS values for these time points were 5.7±1.7 kPa and 5.0±0.5 kPa, respectively. When LS values were analyzed versus duration from Sx-onset, they were found to increase and peak 8-9 days later (Fig.   2 ). It then decreased 7.08 kPa at 20 days after Sx-onset and 5.5 kPa at 45 days after Sx-onset.
Discussion
This study was undertaken to explore the hypothesis that severe hepatic necroinflammation influences LS and to determine whether only ALT level is related to changes in LS, as has been previously claimed. Theoretically, it would be better if liver biopsies were used to stage liver fibrosis, but biopsies could not be performed in our patients because the presence of AHA is not included in the indications for liver biopsy. We tried to minimize the likelihood of including patients with advanced liver fibrosis by excluding those with a previous or family ALT, alanine aminotransferase; Sx-onset day, the day of acute hepatitis symptom onset; LSMperformed day, the day when liver stiffness was measured; peak-ALT day, the day when serum ALT levels peaked; peak-bilirubin day, the day when serum bilirubin levels peaked. kPa, kilopascal; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Sx-onset day, the day of acute hepatitis symptom onset; LSM-performed day, the day when liver stiffness was measured; peak-ALT day, the day when serum ALT levels peaked; peak-bilirubin day, the day when serum bilirubin levels peaked; SE, standard error; OR, odds ratio; CI, confidence interval. Third, in the other study, only the relations between LS and serum AST or ALT were analyzed, and thus, no comment could be made concerning the effects of other factors like bilirubin level or acute hepatitis phase. 24 Our results showed that only serum bilirubin level was significantly correlated with LS during admission, which concurs with a previous report. 25 In this report, it was suggested that LS might be influenced by intrahepatic cholestasis.
However, a recent study, which included patients with chronic cholestatic diseases (including primary biliary cirrhosis and primary sclerosing cholangitis), found that LS values were similar to those found in patients with chronic hepatitis C, although bilirubin levels were higher than in chronic hepatitis C. 20 These findings might suggest that LS is correlated with serum bilirubin level because serum bilirubin represents degree of hepatic necroinflammation more precisely than serum AST or ALT, and not because serum bilirubin represents the degree of intrahepatic cholestasis. Perhaps, increased cell densities caused by inflammatory cell infiltration and cell edema during acute hepatitis 27 could be responsible for increased LS during the acute phase.
Our results suggest that LS increases for 8-9
days after Sx-onset, which lies between peak-ALT (6 days after Sx-onset) and peak-bilirubin (10 days after Sx-onset) and suggests that LS changes are dependent on the phase of acute hepatitis, and that they are not directly related to serum ALT or bilirubin levels.
In the present study, the upper limit of normal LS was defined as 7.08 kPa, because recently, Roulot et al 26 reported a mean LS in 429 healthy subjects of 5.49±1.59 kPa. 26 However, this upper limit appears to be too high, because it is similar to previously reported cutoff value for significant fibrosis in chronic hepatitis. 15, 20, 21 In their study, 26 13.8% of all patients had metabolic syndrome, and no liver biopsy was performed, and thus, patients with liver fibrosis due to nonalcoholic steatohepatitis might had been included among their "healthy subjects", which might have caused 
